Loading
DNA and Nucleic Acid Chemistry · Journal article
Analytical Chemistry · August 9, 2026
Raises a question worth testing. It does not answer one.
This is a nanodevice design study demonstrating in vitro proof-of-concept for a light-gated DNA platform targeting triple-marker breast cancer cells. The work is exploratory and mechanistic; it establishes that the device can integrate multiplexed recognition, light-controlled activation, and electrochemical reporting in cell culture, but does not yet establish efficacy, safety, or clinical relevance.
Journal article. MCF-7 human breast cancer cells in culture. Intervention: Light-gated DNA nanoclaw machine (L-DNM) with photocleavable aptamer targeting EpCAM, MUC1, and NCL, delivering Met inhibitor upon UV activation.
L-DNM achieved high-specificity recognition of triple-marker signature (EpCAM, MUC1, NCL) on MCF-7 human breast cancer cells Photocleavable aptamer design keeps Met-inhibiting function biologically inert until UV activation, enabling spatiotemporal control of RTK inhibition System couples therapeutic activation with electrochemiluminescence reporting with high signal-to-noise ratio in complex matrices
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is an early-stage proof-of-concept study of a novel nanodevice design using in vitro cell culture; it demonstrates feasibility and mechanism but provides no clinical efficacy data, animal studies, or comparison to existing therapeutics.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Cell membrane receptors are pivotal targets in precise therapeutics, yet their ubiquitous expression across tissues remains a fundamental barrier to achieving cell-specific intervention. To overcome the limitations of conventional monotargeting approaches, we developed a light-gated DNA nanoclaw machine (L-DNM) that integrates high-specificity recognition, spatiotemporally controlled therapy, and real-time monitoring of molecular activation within a unified nanoplatform. The L-DNM employed a multivalent targeting mechanism directed against a triple-marker signature, epithelial cell adhesion molecule (EpCAM), MUC1, and nucleolin (NCL), achieving exceptional targeting accuracy toward MCF-7 human breast cancer cells even in heterogeneous environments. Its novel photocleavable aptamer design ensures that the Met-inhibiting function remains biologically inert until activated by UV irradiation. This strategy enables precise spatiotemporal control over receptor tyrosine kinase (RTK) inhibition with minimal off-target effects. Furthermore, the system couples therapeutic activation with instantaneous electrochemiluminescence (ECL) reporting, transforming molecular recognition events into quantifiable signals with high signal-to-noise ratio in complex matrices. By unifying multiplexed targeting, light-gated activation, and self-reporting capability, the L-DNM platform represents a transformative shift from conventional therapeutics to adaptive, intelligent theranostic systems.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.